Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects-Reference-Cited by-同舟云学术

Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects

Published:2016-12-26 Issue:5 Volume:57 Page:592-605
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Dymond Angela W.¹,Martin Paul¹,So Karen²,Huang Yifan³,Severin Paul⁴,Holmes Victoria²,Mariani Gabriella²,Marbury Thomas⁵

Affiliation:

1. AstraZeneca Macclesfield UK

2. AstraZeneca Cambridge UK

3. AstraZeneca Wilmington DE USA

4. Covance Laboratories Inc., Madison WI USA

5. Orlando Clinical Research Center Orlando FL USA

Funder

AstraZeneca

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.848

Reference16 articles.

1. Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

2. The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

3. Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice

4. A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

5. Effects of Cytochrome P450 (CYP3A4 and CYP2C19) Inhibition and Induction on the Exposure of Selumetinib, a MEK1/2 inhibitor, in Healthy Subjects: Results from Two Randomized Trials;Dymond AW;Eur J Clin Pharmacol

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions;Clinical and Translational Science;2024-05

2. A Population Pharmacokinetic Assessment of the Effect of Food on Selumetinib in Patients with Neurofibromatosis Type 1‐Related Plexiform Neurofibromas and Healthy Volunteers;Clinical Pharmacology in Drug Development;2024-04-09

3. Management of cancer treatments in hemodialysis patients;Bulletin du Cancer;2023-03

4. A Phase I, Open-label, Randomized, Crossover Study of the Relative Bioavailability of Capsule and Granule Formulations of Selumetinib;Clinical Therapeutics;2022-04

5. Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib;Clinical Pharmacokinetics;2020-12-23